APA Guidelines Bundle

Treatment of Patients with Schizophrenia

APA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1303678

Contents of this Issue

Navigation

Page 26 of 29

27 Diphenhydramine Benadryl Trihexyphenidyl hydrochloride Artane Acute dystonia, parkinsonism Acute dystonia, parkinsonism Histamine H1 antagonist Muscarinic antagonist Capsule: 25, 50 Oral elixir: 12.5/5 mL Oral solution: 12.5/5 mL, 6.25/1 mL Tablet: 25, 50 Solution, injection: 50/1 mL Other brand name formulations are available for allergy relief Oral elixir: 0.4/mL (473 mL) Tablet: 2, 5 Oral: 75–200 Solution, injection: 10–50 Oral: 5–15 40%–70% 100% 1–4 1.3 76%–85% Not known Hepatic Not known Extensively hepatic N-demethylation via CYP2D6; minor demethylation via CYP1A2, CYP2C9 and CYP2C19; inhibits CYP2D6 (weak) None known Inactive Not known 4–8 4 Urine (as metabolites and unchanged drug) Urine and bile No dose adjustments noted in labeling No dose adjustments noted in labeling

Articles in this issue

Archives of this issue

view archives of APA Guidelines Bundle - Treatment of Patients with Schizophrenia